Speaker illustration

Professor Elizabeth A Magnuson

Saint Luke's Hospital, Kansas City (United States of America)

Hospitalization-related costs among patients with atrial fibrillation treated with the factor Xa inhibitor edoxaban vs warfarin: results from the ENGAGE AF-TIMI 48 trial

Event: ESC CONGRESS 2016

Topic: Atrial fibrillation (AF)

Session: Antithrombotic therapy in atrial fibrillation 2

Thumbnail

This platform is supported by

logo Novo Nordisk